Zynlonta® (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell l

STOCKHOLM, Dec. 21, 2022 /PRNewswire/ -- Sobi® and ADC Therapeutics SA today announced that the European...

Related Keywords

Norway ,Iceland ,United States ,New Jersey ,Stockholm ,Sweden ,Liechtenstein ,Switzerland ,London ,City Of ,United Kingdom ,America ,Lausanne Biop ,Anders Ullman ,Prnewswire Sobi ,Linkedin ,Company On Twitter ,European Commission ,Drug Administration ,Sobi Investor Relations Team ,Youtube ,Committee For Orphan Medicinal Products ,European Union ,Head Of Research Development ,Medicinal Products ,Human Use ,European Medicines Agency ,Medical Affairs ,Chief Medical Officer ,Ameet Mallik ,Chief Executive Officer ,Orphan Medicinal Products ,San Francisco Bay Area ,North America ,Middle East ,Sobi Media ,